144 related articles for article (PubMed ID: 8867870)
1. Clocinnamox antagonism of opioid suppression of schedule-controlled responding in rhesus monkeys.
Butelman ER; Negus SS; Lewis JW; Woods JH
Psychopharmacology (Berl); 1996 Feb; 123(4):320-4. PubMed ID: 8867870
[TBL] [Abstract][Full Text] [Related]
2. Effects of opioid agonists selective for mu, kappa and delta opioid receptors on schedule-controlled responding in rhesus monkeys: antagonism by quadazocine.
Negus SS; Burke TF; Medzihradsky F; Woods JH
J Pharmacol Exp Ther; 1993 Nov; 267(2):896-903. PubMed ID: 8246165
[TBL] [Abstract][Full Text] [Related]
3. Opioid interactions in rhesus monkeys: effects of delta + mu and delta + kappa agonists on schedule-controlled responding and thermal nociception.
Stevenson GW; Folk JE; Linsenmayer DC; Rice KC; Negus SS
J Pharmacol Exp Ther; 2003 Dec; 307(3):1054-64. PubMed ID: 14557380
[TBL] [Abstract][Full Text] [Related]
4. Clocinnamox distinguishes opioid agonists according to relative efficacy in normal and morphine-treated rats trained to discriminate morphine.
Walker EA; Young AM
J Pharmacol Exp Ther; 2002 Jul; 302(1):101-10. PubMed ID: 12065706
[TBL] [Abstract][Full Text] [Related]
5. Kappa opioid antagonist effects of the novel kappa antagonist 5'-guanidinonaltrindole (GNTI) in an assay of schedule-controlled behavior in rhesus monkeys.
Negus SS; Mello NK; Linsenmayer DC; Jones RM; Portoghese PS
Psychopharmacology (Berl); 2002 Oct; 163(3-4):412-9. PubMed ID: 12373442
[TBL] [Abstract][Full Text] [Related]
6. Methoclocinnamox: agonist and antagonist effects of a novel long-lasting opioid in rhesus monkeys.
Butelman ER; Lewis JW; Woods JH
J Pharmacol Exp Ther; 1996 Nov; 279(2):934-8. PubMed ID: 8930202
[TBL] [Abstract][Full Text] [Related]
7. kappa-Opioid receptor effects of butorphanol in rhesus monkeys.
Vivian JA; DeYoung MB; Sumpter TL; Traynor JR; Lewis JW; Woods JH
J Pharmacol Exp Ther; 1999 Jul; 290(1):259-65. PubMed ID: 10381785
[TBL] [Abstract][Full Text] [Related]
8. The effect of the irreversible mu-opioid receptor antagonist clocinnamox on morphine potency, receptor binding and receptor mRNA.
Chan K; Brodsky M; Davis T; Franklin S; Inturrisi CE; Yoburn BC
Eur J Pharmacol; 1995 Dec; 287(2):135-43. PubMed ID: 8749027
[TBL] [Abstract][Full Text] [Related]
9. Methocinnamox is a potent, long-lasting, and selective antagonist of morphine-mediated antinociception in the mouse: comparison with clocinnamox, beta-funaltrexamine, and beta-chlornaltrexamine.
Broadbear JH; Sumpter TL; Burke TF; Husbands SM; Lewis JW; Woods JH; Traynor JR
J Pharmacol Exp Ther; 2000 Sep; 294(3):933-40. PubMed ID: 10945843
[TBL] [Abstract][Full Text] [Related]
10. In vivo determination of mu opioid receptor turnover in rhesus monkeys after irreversible blockade with clocinnamox.
Zernig G; Butelman ER; Lewis JW; Walker EA; Woods JH
J Pharmacol Exp Ther; 1994 Apr; 269(1):57-65. PubMed ID: 8169852
[TBL] [Abstract][Full Text] [Related]
11. Studies of tolerance and dependence with the delta-opioid agonist SNC80 in rhesus monkeys responding under a schedule of food presentation.
Brandt MR; Furness MS; Rice KC; Fischer BD; Negus SS
J Pharmacol Exp Ther; 2001 Nov; 299(2):629-37. PubMed ID: 11602675
[TBL] [Abstract][Full Text] [Related]
12. Clocinnamox dose-dependently antagonizes morphine-analgesia and [3H]DAMGO binding in rats.
Paronis CA; Woods JH
Eur J Pharmacol; 1997 Oct; 337(1):27-34. PubMed ID: 9389377
[TBL] [Abstract][Full Text] [Related]
13. Clocinnamox inhibits the intravenous self-administration of opioid agonists in rhesus monkeys: comparison with effects on opioid agonist-mediated antinociception.
Zernig G; Lewis JW; Woods JH
Psychopharmacology (Berl); 1997 Feb; 129(3):233-42. PubMed ID: 9084061
[TBL] [Abstract][Full Text] [Related]
14. Mechanism of clocinnamox blockade of opioid receptors: evidence from in vitro and ex vivo binding and behavioral assays.
Zernig G; Burke T; Lewis JW; Woods JH
J Pharmacol Exp Ther; 1996 Oct; 279(1):23-31. PubMed ID: 8858971
[TBL] [Abstract][Full Text] [Related]
15. Delta opioid antagonist effects of buprenorphine in rhesus monkeys.
Negus SS; Bidlack JM; Mello NK; Furness MS; Rice KC; Brandt MR
Behav Pharmacol; 2002 Nov; 13(7):557-70. PubMed ID: 12409994
[TBL] [Abstract][Full Text] [Related]
16. Effects of the structurally novel opioid 14 alpha, 14' beta-[dithiobis [(2-oxo-2,1-ethanediyl)imino]]bis(7,8-dihydromorphinone) on schedule-controlled behavior and thermal nociception in rhesus monkeys.
Gatch MB; Negus SS; Mello NK; Archer S; Bidlack JM
J Pharmacol Exp Ther; 1996 Sep; 278(3):1282-9. PubMed ID: 8819513
[TBL] [Abstract][Full Text] [Related]
17. Differentiation of kappa opioid agonist-induced antinociception by naltrexone apparent pA2 analysis in rhesus monkeys.
Ko MC; Butelman ER; Traynor JR; Woods JH
J Pharmacol Exp Ther; 1998 May; 285(2):518-26. PubMed ID: 9580592
[TBL] [Abstract][Full Text] [Related]
18. Methoclocinnamox: time course of changes in alfentanil-reinforced responding in rhesus monkeys.
Briscoe RJ; Winger G; Lewis JW; Woods JH
Psychopharmacology (Berl); 2000 Mar; 148(4):393-9. PubMed ID: 10928312
[TBL] [Abstract][Full Text] [Related]
19. Interactions between delta and mu opioid agonists in assays of schedule-controlled responding, thermal nociception, drug self-administration, and drug versus food choice in rhesus monkeys: studies with SNC80 [(+)-4-[(alphaR)-alpha-((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]-N,N-diethylbenzamide] and heroin.
Stevenson GW; Folk JE; Rice KC; Negus SS
J Pharmacol Exp Ther; 2005 Jul; 314(1):221-31. PubMed ID: 15792997
[TBL] [Abstract][Full Text] [Related]
20. Opioid agonist efficacy predicts the magnitude of tolerance and the regulation of mu-opioid receptors and dynamin-2.
Pawar M; Kumar P; Sunkaraneni S; Sirohi S; Walker EA; Yoburn BC
Eur J Pharmacol; 2007 Jun; 563(1-3):92-101. PubMed ID: 17349996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
